| Literature DB >> 32161321 |
Junya Kanda1, Katsutsugu Umeda2, Koji Kato3,4, Makoto Murata5, Junichi Sugita6, Souichi Adachi7, Katsuyoshi Koh8, Maiko Noguchi9, Hiroaki Goto10, Nao Yoshida3, Maho Sato11, Yuhki Koga12, Tsukasa Hori13, Yuko Cho14, Atsushi Ogawa15, Masami Inoue11, Yoshiko Hashii16, Yoshiko Atsuta17,18, Takanori Teshima6.
Abstract
The effect of GVHD on transplant outcomes after unrelated cord blood transplantation (UCBT) is not yet fully understood. Pediatric patients aged 0-15 years with acute leukemia or myelodysplastic syndrome who underwent their first UCBT (n = 740) were selected from the Japanese registry. Fifty percent of the patients received a UCB unit containing more than 5.0 × 107/kg total nucleated cells. The occurrence of grade III-IV acute GVHD was associated with a higher risk of non-relapse mortality (NRM, hazard ratio [HR] 4.07, P < 0.001) compared with no acute GVHD. Grade I-II acute GVHD was not associated with NRM. The occurrence of grade I-II or grade III-IV acute GVHD was not associated with a relapse risk. These findings showed that grade I-II acute GVHD carried no survival benefit and grade III-IV acute GVHD had an adverse effect (HR 1.68, P = 0.007). The occurrence of limited chronic GVHD was associated with a low risk of overall mortality (HR 0.60, P = 0.045). Severe acute GVHD should be prevented because of its association with high overall mortality and NRM in pediatric single UCBT. Mild acute GVHD provides no overall benefit. Mild chronic GVHD may be beneficial for survival.Entities:
Mesh:
Year: 2020 PMID: 32161321 DOI: 10.1038/s41409-020-0853-1
Source DB: PubMed Journal: Bone Marrow Transplant ISSN: 0268-3369 Impact factor: 5.483